Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification

Hsiang Po Huang, Pin Hsun Chen, Wuh Liang Hwu, Ching Yu Chuang, Yin Hsiu Chien, Lee Stone, Chung Liang Chien, Li Tzu Li, Shu Chuan Chiang, Hsin Fu Chen, Hong Nerng Ho, Chung Hsuan Chen, Hung Chih Kuo

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Pompe disease is caused by autosomal recessive mutations in the acid alpha-glucosidase (GAA) gene, which encodes GAA. Although enzyme replacement therapy has recently improved patient survival greatly, the results in skeletal muscles and for advanced disease are still not satisfactory. Here, we report the derivation of Pompe disease-induced pluripotent stem cells (PomD-iPSCs) from two patients with different GAA mutations and their potential for pathogenesis modeling, drug testing and disease marker identification. PomD-iPSCs maintained pluripotent features and had low GAA activity and high glycogen content. Cardiomyocyte-like cells (CMLCs) differentiated from PomD-iPSCs recapitulated the hallmark Pompe disease pathophysiological phenotypes, including high levels of glycogen and multiple ultrastructural aberrances. Drug rescue assessment showed that exposure of PomD-iPSC-derived CMLCs to recombinant human GAA reversed the major pathologic phenotypes. Furthermore, l-carnitine treatment reduced defective cellular respiration in the diseased cells. By comparative transcriptome analysis, we identified glycogen metabolism, lysosome and mitochondria-related marker genes whose expression robustly correlated with the therapeutic effect of drug treatment in PomD-iPSC-derived CMLCs. Collectively, these results demonstrate that PomD-iPSCs are a promising in vitro disease model for the development of novel therapeutic strategies for Pompe disease.

Original languageEnglish
Article numberddr424
Pages (from-to)4851-4864
Number of pages14
JournalHuman Molecular Genetics
Volume20
Issue number24
DOIs
Publication statusPublished - Dec 1 2011

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. / Huang, Hsiang Po; Chen, Pin Hsun; Hwu, Wuh Liang; Chuang, Ching Yu; Chien, Yin Hsiu; Stone, Lee; Chien, Chung Liang; Li, Li Tzu; Chiang, Shu Chuan; Chen, Hsin Fu; Ho, Hong Nerng; Chen, Chung Hsuan; Kuo, Hung Chih.

In: Human Molecular Genetics, Vol. 20, No. 24, ddr424, 01.12.2011, p. 4851-4864.

Research output: Contribution to journalArticle

Huang, HP, Chen, PH, Hwu, WL, Chuang, CY, Chien, YH, Stone, L, Chien, CL, Li, LT, Chiang, SC, Chen, HF, Ho, HN, Chen, CH & Kuo, HC 2011, 'Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification', Human Molecular Genetics, vol. 20, no. 24, ddr424, pp. 4851-4864. https://doi.org/10.1093/hmg/ddr424
Huang, Hsiang Po ; Chen, Pin Hsun ; Hwu, Wuh Liang ; Chuang, Ching Yu ; Chien, Yin Hsiu ; Stone, Lee ; Chien, Chung Liang ; Li, Li Tzu ; Chiang, Shu Chuan ; Chen, Hsin Fu ; Ho, Hong Nerng ; Chen, Chung Hsuan ; Kuo, Hung Chih. / Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. In: Human Molecular Genetics. 2011 ; Vol. 20, No. 24. pp. 4851-4864.
@article{3a7a80e15c2647faa0d0c6b3ce21eb00,
title = "Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification",
abstract = "Pompe disease is caused by autosomal recessive mutations in the acid alpha-glucosidase (GAA) gene, which encodes GAA. Although enzyme replacement therapy has recently improved patient survival greatly, the results in skeletal muscles and for advanced disease are still not satisfactory. Here, we report the derivation of Pompe disease-induced pluripotent stem cells (PomD-iPSCs) from two patients with different GAA mutations and their potential for pathogenesis modeling, drug testing and disease marker identification. PomD-iPSCs maintained pluripotent features and had low GAA activity and high glycogen content. Cardiomyocyte-like cells (CMLCs) differentiated from PomD-iPSCs recapitulated the hallmark Pompe disease pathophysiological phenotypes, including high levels of glycogen and multiple ultrastructural aberrances. Drug rescue assessment showed that exposure of PomD-iPSC-derived CMLCs to recombinant human GAA reversed the major pathologic phenotypes. Furthermore, l-carnitine treatment reduced defective cellular respiration in the diseased cells. By comparative transcriptome analysis, we identified glycogen metabolism, lysosome and mitochondria-related marker genes whose expression robustly correlated with the therapeutic effect of drug treatment in PomD-iPSC-derived CMLCs. Collectively, these results demonstrate that PomD-iPSCs are a promising in vitro disease model for the development of novel therapeutic strategies for Pompe disease.",
author = "Huang, {Hsiang Po} and Chen, {Pin Hsun} and Hwu, {Wuh Liang} and Chuang, {Ching Yu} and Chien, {Yin Hsiu} and Lee Stone and Chien, {Chung Liang} and Li, {Li Tzu} and Chiang, {Shu Chuan} and Chen, {Hsin Fu} and Ho, {Hong Nerng} and Chen, {Chung Hsuan} and Kuo, {Hung Chih}",
year = "2011",
month = "12",
day = "1",
doi = "10.1093/hmg/ddr424",
language = "English",
volume = "20",
pages = "4851--4864",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "24",

}

TY - JOUR

T1 - Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification

AU - Huang, Hsiang Po

AU - Chen, Pin Hsun

AU - Hwu, Wuh Liang

AU - Chuang, Ching Yu

AU - Chien, Yin Hsiu

AU - Stone, Lee

AU - Chien, Chung Liang

AU - Li, Li Tzu

AU - Chiang, Shu Chuan

AU - Chen, Hsin Fu

AU - Ho, Hong Nerng

AU - Chen, Chung Hsuan

AU - Kuo, Hung Chih

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Pompe disease is caused by autosomal recessive mutations in the acid alpha-glucosidase (GAA) gene, which encodes GAA. Although enzyme replacement therapy has recently improved patient survival greatly, the results in skeletal muscles and for advanced disease are still not satisfactory. Here, we report the derivation of Pompe disease-induced pluripotent stem cells (PomD-iPSCs) from two patients with different GAA mutations and their potential for pathogenesis modeling, drug testing and disease marker identification. PomD-iPSCs maintained pluripotent features and had low GAA activity and high glycogen content. Cardiomyocyte-like cells (CMLCs) differentiated from PomD-iPSCs recapitulated the hallmark Pompe disease pathophysiological phenotypes, including high levels of glycogen and multiple ultrastructural aberrances. Drug rescue assessment showed that exposure of PomD-iPSC-derived CMLCs to recombinant human GAA reversed the major pathologic phenotypes. Furthermore, l-carnitine treatment reduced defective cellular respiration in the diseased cells. By comparative transcriptome analysis, we identified glycogen metabolism, lysosome and mitochondria-related marker genes whose expression robustly correlated with the therapeutic effect of drug treatment in PomD-iPSC-derived CMLCs. Collectively, these results demonstrate that PomD-iPSCs are a promising in vitro disease model for the development of novel therapeutic strategies for Pompe disease.

AB - Pompe disease is caused by autosomal recessive mutations in the acid alpha-glucosidase (GAA) gene, which encodes GAA. Although enzyme replacement therapy has recently improved patient survival greatly, the results in skeletal muscles and for advanced disease are still not satisfactory. Here, we report the derivation of Pompe disease-induced pluripotent stem cells (PomD-iPSCs) from two patients with different GAA mutations and their potential for pathogenesis modeling, drug testing and disease marker identification. PomD-iPSCs maintained pluripotent features and had low GAA activity and high glycogen content. Cardiomyocyte-like cells (CMLCs) differentiated from PomD-iPSCs recapitulated the hallmark Pompe disease pathophysiological phenotypes, including high levels of glycogen and multiple ultrastructural aberrances. Drug rescue assessment showed that exposure of PomD-iPSC-derived CMLCs to recombinant human GAA reversed the major pathologic phenotypes. Furthermore, l-carnitine treatment reduced defective cellular respiration in the diseased cells. By comparative transcriptome analysis, we identified glycogen metabolism, lysosome and mitochondria-related marker genes whose expression robustly correlated with the therapeutic effect of drug treatment in PomD-iPSC-derived CMLCs. Collectively, these results demonstrate that PomD-iPSCs are a promising in vitro disease model for the development of novel therapeutic strategies for Pompe disease.

UR - http://www.scopus.com/inward/record.url?scp=81855172517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855172517&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddr424

DO - 10.1093/hmg/ddr424

M3 - Article

VL - 20

SP - 4851

EP - 4864

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 24

M1 - ddr424

ER -